


# Breast Cancer: Diagnostic Imaging and Therapeutic Guidance

Uwe Fischer  
Friedemann Baum  
Susanne Luftner-Nagel









# Breast Cancer: Diagnostic Imaging and Therapeutic Guidance

**Uwe Fischer, MD**

Professor

Women's Health Care Center

Göttingen, Germany

**Friedemann Baum, MD**

Women's Health Care Center

Göttingen, Germany

**Susanne Luftner-Nagel, MD**

Women's Health Care Center

Göttingen, Germany

545 illustrations

Thieme

Stuttgart • New York • Delhi • Rio de Janeiro

**Library of Congress Cataloging-in-Publication Data**  
is available from the publisher.

This book is an authorized translation of the first German edition published and copyrighted 2014 by Georg Thieme Verlag, Stuttgart. Title of the German edition: Diagnostik und Therapie des Mammakarzinoms

Translators: Elizabeth Crawford, Göttingen, Germany; Alan Wiser, Ambler, PA, USA

Illustrator: Barbara Gay, Bremen, Germany

**Important note:** Medicine is an ever-changing science undergoing continual development. Research and clinical experience are continually expanding our knowledge, in particular our knowledge of proper treatment and drug therapy. Insofar as this book mentions any dosage or application, readers may rest assured that the authors, editors, and publishers have made every effort to ensure that such references are in accordance with **the state of knowledge at the time of production of the book.**

Nevertheless, this does not involve, imply, or express any guarantee or responsibility on the part of the publishers in respect to any dosage instructions and forms of applications stated in the book. **Every user is requested to examine carefully** the manufacturers' leaflets accompanying each drug and to check, if necessary in consultation with a physician or specialist, whether the dosage schedules mentioned therein or the contraindications stated by the manufacturers differ from the statements made in the present book. Such examination is particularly important with drugs that are either rarely used or have been newly released on the market. Every dosage schedule or every form of application used is entirely at the user's own risk and responsibility. The authors and publishers request every user to report to the publishers any discrepancies or inaccuracies noticed. If errors in this work are found after publication, errata will be posted at [www.thieme.com](http://www.thieme.com) on the product description page.

Some of the product names, patents, and registered designs referred to in this book are in fact registered trademarks or proprietary names even though specific reference to this fact is not always made in the text. Therefore, the appearance of a name without designation as proprietary is not to be construed as a representation by the publisher that it is in the public domain.

© 2018 Georg Thieme Verlag KG

Thieme Publishers Stuttgart  
Rüdigerstrasse 14, 70469 Stuttgart, Germany  
+49 [0]711 8931 421, [customerservice@thieme.de](mailto:customerservice@thieme.de)

Thieme Publishers New York  
333 Seventh Avenue, New York, NY 10001 USA  
+1 800 782 3488, [customerservice@thieme.com](mailto:customerservice@thieme.com)

Thieme Publishers Delhi  
A-12, Second Floor, Sector-2, Noida-201301  
Uttar Pradesh, India  
+91 120 45 566 00, [customerservice@thieme.in](mailto:customerservice@thieme.in)


Thieme Publishers Rio de Janeiro, Thieme Publicações Ltda.  
Edifício Rodolpho de Paoli, 25º andar  
Av. Nilo Peçanha, 50 – Sala 2508  
Rio de Janeiro 20020-906 Brasil  
+55 21 3172 2297 / +55 21 3172 1896

Cover design: Thieme Publishing Group

Typesetting by DiTech Process Solutions Pvt. Ltd., India  
Printed in China by Everbest Printing Ltd., Hong Kong

ISBN 978-3-13-201931-7

Also available as an e-book:  
eISBN 978-3-13-201941-6



5 4 3 2 1

This book, including all parts thereof, is legally protected by copyright. Any use, exploitation, or commercialization outside the narrow limits set by copyright legislation without the publisher's consent is illegal and liable to prosecution. This applies in particular to photostat reproduction, copying, mimeographing or duplication of any kind, translating, preparation of microfilms, and electronic data processing and storage.

# Contents

## Part 1: Anatomy, Physiology, and Pathology of the Breast

<b>1</b>	<b>Development, Anatomy, and Physiology of the Mammary Gland</b> .....	2
	<i>F. Baum</i>	
1.1	Development .....	2
1.2	Anatomy .....	2
<b>2</b>	<b>Tumor Formation</b> .....	4
	<i>F. Baum</i>	
2.1	Mutation, Carcinogenesis, and Angiogenesis .....	4
2.2	Risk Factors .....	4
2.3	Genetic Risk Factors .....	5
2.4	Prevention .....	6
2.4.1	Primary Prevention .....	6
2.4.2	Secondary Prevention .....	6
2.4.3	Tertiary Prevention .....	6
2.5	Epidemiology, Incidence, and Mortality .....	6
	Bibliography .....	7
<b>3</b>	<b>Pathology of Benign and Malignant Changes in the Breast</b> .....	9
	<i>J. Rueschoff</i>	
3.1	Benign Changes .....	9
3.1.1	Histological Principles .....	9
3.1.2	Nonneoplastic, Nonproliferative Diseases of the Breast .....	9
3.1.3	Benign Tumor-Forming Diseases .....	11
3.2	Malignant Changes in the Breast .....	19
3.2.1	Classification of Malignant Breast Tumors (WHO Classification, B-Categories) .....	19
3.2.2	Prognostic and Predictive Factors .....	20
3.2.3	Papillary Lesions .....	24
3.2.4	Ductal Carcinoma In Situ .....	25
3.2.5	Microinvasive and Invasive Breast Carcinoma .....	26
3.2.6	Tumors of the Nipple .....	29
3.2.7	Malignant Mesenchymal Tumors and Lymphomas of the Breast .....	29
3.2.8	Metastatic Tumors .....	30
3.3	Acknowledgments .....	31
	Bibliography .....	31

## Part 2: Breast Diagnostics

<b>4</b>	<b>Nonimaging Diagnostics</b> .....	34
	<i>U. Fischer</i>	
4.1	History .....	34
4.2	Informed Consent .....	34
4.3	Self-Examination .....	34
4.4	Inspection .....	34
4.5	Palpation .....	35
	Bibliography .....	40
<b>5</b>	<b>Mammography</b> .....	41
	<i>U. Fischer</i>	
5.1	Technique and Methods .....	41
5.1.1	Principles of X-ray Mammography .....	41
5.1.2	Components of a Mammography System .....	41
5.1.3	Exposure Parameters .....	43
5.1.4	Image Quality .....	43
5.1.5	Analog Mammography .....	44
5.1.6	Digital Mammography .....	45
5.1.7	Radiation Exposure .....	54

<b>5.2</b>	<b>Parameters and Positioning</b>	55	<b>5.3.1</b>	Terminology	62
5.2.1	Standard Projections	55	<b>5.3.2</b>	Tissue Density in a Mammogram According to the ACR BI-RADS Atlas	63
5.2.2	Supplementary Views	57	<b>5.3.3</b>	Interpretation Criteria	64
5.2.3	Galactography	58	<b>5.3.4</b>	BI-RADS Classification of Mammography	68
5.2.4	Mammography of the Male Breast	61	<b>5.3.5</b>	Normal Findings in the Mammogram	74
5.2.5	Quality Assurance in Parameters and Positioning	61		<b>Bibliography</b>	74
<b>5.3</b>	<b>Interpretation of Mammograms</b>	62			
<b>6</b>	<b>Breast Ultrasonography</b>	77			
	<i>S. Luftner-Nagel</i>				
<b>6.1</b>	<b>Technique and Methods</b>	77	<b>6.2.1</b>	Terminology	84
6.1.1	Basic Principles	77	<b>6.2.2</b>	Tissue Type in Sonography	84
6.1.2	Device Adjustments	79	<b>6.2.3</b>	Evaluation Criteria	85
6.1.3	Examination Technique	79	<b>6.2.4</b>	BI-RADS Classification of Breast Ultrasonography	89
6.1.4	Ultrasound Techniques	81	<b>6.2.5</b>	Normal Findings in Sonography	92
6.1.5	Quality Assurance	84		<b>Bibliography</b>	93
<b>6.2</b>	<b>Evaluation</b>	84			
<b>7</b>	<b>Magnetic Resonance Imaging of the Breast</b>	94			
	<i>U. Fischer</i>				
<b>7.1</b>	<b>Technique and Methods</b>	94	<b>7.2.1</b>	Terminology	101
7.1.1	Basic Principles	94	<b>7.2.2</b>	Perfusion Pattern	101
7.1.2	Tumor Detection	95	<b>7.2.3</b>	Findings in the T1-Weighted Precontrast Image	101
7.1.3	Equipment	95	<b>7.2.4</b>	Findings in the T2-Weighted Image	102
7.1.4	Timing of the Examination	95	<b>7.2.5</b>	Findings in the T1-Weighted Contrast-Enhanced Image	102
7.1.5	Patient Positioning	96	<b>7.2.6</b>	Evaluation Criteria	103
7.1.6	Measurement Parameters	96	<b>7.2.7</b>	BI-RADS Classification of MRI of the Breast	104
7.1.7	Image Postprocessing	97	<b>7.2.8</b>	Normal Findings in MRI of the Breast	107
7.1.8	Implant Evaluation	99		<b>Bibliography</b>	107
7.1.9	Nonestablished Examination Techniques	100			
<b>7.2</b>	<b>Evaluation</b>	101			
<b>8</b>	<b>Imaging of Breast Lesions</b>	110			
	<i>U. Fischer and S. Luftner-Nagel</i>				
<b>8.1</b>	<b>Benign Findings</b>	110	<b>8.1.17</b>	Seroma	128
8.1.1	Cysts	110	<b>8.1.18</b>	Hematoma	129
8.1.2	Inflamed Cysts	110	<b>8.1.19</b>	Fat Necrosis (Oil Cyst)	130
8.1.3	Complex Cysts	111	<b>8.1.20</b>	Abscess	131
8.1.4	Myxoid Fibroadenoma	112	<b>8.1.21</b>	Postoperative Scars	132
8.1.5	Fibrotic Fibroadenoma	114	<b>8.2</b>	<b>Findings with Ambiguous Biological Potential</b>	133
8.1.6	Adenoma	116	<b>8.2.1</b>	Papillomas	133
8.1.7	Hamartoma	116	<b>8.2.2</b>	Radial Scars	135
8.1.8	Lipoma	117	<b>8.2.3</b>	Atypical Ductal Hyperplasia	135
8.1.9	Mammary Fibrosis	119	<b>8.2.4</b>	Phyllodes Tumors	136
8.1.10	Adenosis of the Breast	120	<b>8.2.5</b>	Cysts with Intracystic Proliferation	138
8.1.11	Fibrocystic Condition of the Breast	121	<b>8.2.6</b>	Lobular Intraepithelial Neoplasia	139
8.1.12	Adenomyoepithelioma	122	<b>8.3</b>	<b>Intraductal Carcinoma</b>	141
8.1.13	Acute Nonpuerperal Mastitis	124	<b>8.3.1</b>	Ductal Carcinoma In Situ (Low Grade)	141
8.1.14	Chronic Nonpuerperal Mastitis	125			
8.1.15	Intramammary Lymph Nodes	125			
8.1.16	Pseudoangiomatous Stromal Hyperplasia	126			



8.3.2	Ductal Carcinoma In Situ (Intermediate Type) . . . . .	141	8.4.5	Mucinous Carcinoma . . . . .	148
8.3.3	Ductal Carcinoma In Situ (High Grade) . . . . .	141	8.4.6	Invasive Papillary Carcinoma . . . . .	150
<b>8.4</b>	<b>Invasive Tumors . . . . .</b>	<b>143</b>	8.4.7	Sarcomas . . . . .	152
8.4.1	Invasive Ductal Carcinoma . . . . .	143	8.4.8	Triple-Negative Carcinoma . . . . .	152
8.4.2	Invasive Lobular Carcinoma . . . . .	145	8.4.9	Paget's Disease of the Nipple . . . . .	152
8.4.3	Tubular Carcinoma . . . . .	147	8.4.10	Inflammatory Carcinoma . . . . .	154
8.4.4	Medullary Carcinoma . . . . .	147	8.4.11	Systemic Diseases Involving the Breast . . . . .	155
<b>9</b>	<b>Breast Intervention . . . . .</b>	<b>158</b>			
	<i>F. Baum</i>				
<b>9.1</b>	<b>Biopsy . . . . .</b>	<b>158</b>			
9.1.1	Objective of Percutaneous Tissue Sampling . . . . .	158	<b>9.2</b>	<b>Localization . . . . .</b>	<b>166</b>
9.1.2	Percutaneous Tissue Sampling Equipment and Implementation . . . . .	158	9.2.1	Objective of Pretherapeutic Localization . . . . .	166
9.1.3	Interventional Imaging . . . . .	161	9.2.2	Equipment and Implementation . . . . .	170
9.1.4	Classification of Findings . . . . .	164	9.2.3	Quality Assurance . . . . .	172
9.1.5	Tumor Seeding and Mechanical Tumor Induction . . . . .	166		<b>Bibliography . . . . .</b>	<b>173</b>
9.1.6	Quality Assurance . . . . .	166			
<b>Part 3: Prevention and Therapy of Breast Cancer</b>					
<b>10</b>	<b>Examination Concepts . . . . .</b>	<b>176</b>			
	<i>U. Fischer</i>				
<b>10.1</b>	<b>Prevention . . . . .</b>	<b>176</b>	<b>10.4</b>	<b>Pretherapeutic Local Staging . . . . .</b>	<b>183</b>
<b>10.2</b>	<b>Early Breast Cancer Detection (Secondary Prevention) . . . . .</b>	<b>176</b>	<b>10.5</b>	<b>Pretherapeutic Peripheral Staging . . . . .</b>	<b>184</b>
10.2.1	Mammography Screening . . . . .	177	<b>10.6</b>	<b>Follow-up Care . . . . .</b>	<b>184</b>
10.2.2	Individualized Examination Concepts . . . . .	180	<b>10.7</b>	<b>Implant Evaluation . . . . .</b>	<b>185</b>
10.2.3	Early Detection in Women with a High-Risk Profile . . . . .	181	<b>10.8</b>	<b>Evaluation of the Male Breast . . . . .</b>	<b>185</b>
10.2.4	Future Concepts of Early Breast Cancer Detection . . . . .	182		<b>Bibliography . . . . .</b>	<b>185</b>
<b>10.3</b>	<b>Diagnostic Work-up . . . . .</b>	<b>183</b>			
<b>11</b>	<b>Surgical Treatment of Breast Carcinoma . . . . .</b>	<b>187</b>			
	<i>T. Kuehn</i>				
<b>11.1</b>	<b>Significance of Surgery in the Context of Multimodal Treatment of Breast Carcinoma . . . . .</b>	<b>187</b>	11.4.1	Procedure for Clinically Negative Node Status . . . . .	195
<b>11.2</b>	<b>Types of Breast Carcinoma . . . . .</b>	<b>187</b>	11.4.2	Procedure for Clinically Positive Nodal Status . . . . .	195
11.2.1	Lesions of Uncertain Biological Potential (B3 Lesions) . . . . .	187	11.4.3	Procedure for Clinically Negative Node Status and Positive Sentinel Node . . . . .	195
11.2.2	Preinvasive Carcinoma (Ductal Carcinoma in Situ; B5a) . . . . .	187	<b>11.5</b>	<b>Secondary Breast Reconstruction . . . . .</b>	<b>196</b>
11.2.3	Invasive Carcinoma (B5b) . . . . .	187	11.5.1	Timing the Reconstruction: Primary vs. Secondary Reconstruction . . . . .	196
<b>11.3</b>	<b>Surgical Treatment of the Primary Lesion . . . . .</b>	<b>189</b>	11.5.2	Alloplastic Reconstruction (Implant Reconstruction) . . . . .	197
11.3.1	Oncologic Aspects . . . . .	189	11.5.3	Autologous Reconstruction (Reconstruction Using Endogenous Tissue) . . . . .	197
11.3.2	Technical Aspects . . . . .	189	11.5.4	Nipple Reconstruction . . . . .	199
<b>11.4</b>	<b>Lymph Node Surgery . . . . .</b>	<b>192</b>		<b>Bibliography . . . . .</b>	<b>200</b>

<b>12</b>	<b>Medical Treatment of Breast Cancer</b> .....	201		
	<i>M. Hellriegel and G. Emons</i>			
<b>12.1</b>	<b>Basic Principles and Objectives</b> .....	201	<b>12.4.1</b>	Endocrine Therapy in Premenopausal Patients with Distant Metastases .....
<b>12.2</b>	<b>Adjuvant Drug Therapy</b> .....	201	<b>12.4.2</b>	Endocrine Therapy in Postmenopausal Patients with Distant Metastases .....
12.2.1	Adjuvant Chemotherapy .....	201	<b>12.5</b>	<b>Endocrine Maintenance Therapy after Completing Chemotherapy</b> .....
12.2.2	Neoadjuvant Therapy .....	202	<b>12.6</b>	<b>Chemotherapy of Metastatic Breast Cancer Combined with New Agents</b> .....
12.2.3	Adjuvant Endocrine Therapy .....	204		<b>Bibliography</b> .....
12.2.4	Antibody Therapy .....	207		
<b>12.3</b>	<b>Medical Treatment in Locoregional Recurrence</b> ....	207		
<b>12.4</b>	<b>Medical Treatment of Distant Metastases</b> .....	208		
<b>13</b>	<b>Radiotherapy of Breast Cancer</b> .....	212		
	<i>C. F. Hess</i>			
<b>13.1</b>	<b>Adjuvant Radiotherapy after Breast-Conserving Surgery</b> .....	212	<b>13.5.3</b>	Shortened Treatment Time: Alternative Fractionation Schemes .....
<b>13.2</b>	<b>Adjuvant Radiotherapy after Mastectomy</b> .....	212	<b>13.6</b>	<b>Acute Side Effects and Complications of Adjuvant Radiation Therapy</b> .....
<b>13.3</b>	<b>Effectiveness of Adjuvant Radiation Therapy: Prognostic Factors</b> .....	213	13.6.1	Acute Side Effects .....
<b>13.4</b>	<b>Integration of Adjuvant Radiotherapy into the Multimodal Treatment Concept</b> .....	213	13.6.2	Late Complications of Radiation Therapy .....
<b>13.5</b>	<b>Target Volume and Dose Concept</b> .....	213	<b>13.7</b>	<b>Planning and Implementing Radiation Therapy</b> ....
13.5.1	Clinical Target Volume: Former Tumor Region, Mammary Gland, Chest Wall, and Regional Lymph Channels .....	214	<b>13.8</b>	<b>Radiotherapy in Primarily Inoperable Tumors, Recurrences, and Metastatic Disease</b> .....
13.5.2	Partial Breast Irradiation .....	215	<b>13.9</b>	<b>Summary</b> .....
				<b>Bibliography</b> .....
<b>14</b>	<b>Management of a Diagnostic Breast Center</b> .....	220		
	<i>F. Baum</i>			
<b>14.1</b>	<b>Expertise</b> .....	220	<b>14.3.3</b>	Breast MRI Room .....
<b>14.2</b>	<b>Equipment</b> .....	220	<b>14.3.4</b>	Rooms for a Second Ultrasound Unit and for Interventional Procedures .....
<b>14.3</b>	<b>Facility Design</b> .....	221	<b>14.3.5</b>	Recovery Room .....
14.3.1	Doctor's Consultation Room .....	221	<b>14.4</b>	<b>Ambiance</b> .....
14.3.2	Mammography and Sonography Rooms .....	221	<b>14.5</b>	<b>Communication</b> .....
<b>15</b>	<b>Logistics in an Interdisciplinary Breast Center</b> .....	225		
	<i>G. Emons</i>			
<b>15.1</b>	<b>Background</b> .....	225	<b>15.4</b>	<b>Outlook</b> .....
<b>15.2</b>	<b>Structure of a Certified Breast Center</b> .....	225		<b>Bibliography</b> .....
<b>15.3</b>	<b>Treatment Pathways in a Breast Center</b> .....	225		
<b>16</b>	<b>Counseling Techniques and Psychosocial Support</b> .....	228		
	<i>H. Lorch, A. Kuechemann, and J. Rueschoff</i>			
<b>16.1</b>	<b>Compliance</b> .....	228	<b>16.1.1</b>	Quality of the Medical Services .....

16.1.2	General and Personal Requirements .....	228	16.3.1	Station 1: Registration .....	230
16.1.3	Structural, Organizational, and Procedural Components .....	228	16.3.2	Station 2: History and Physical Examination .....	231
16.1.4	Interactive and Communicative Competence .....	228	16.3.3	Station 3: The Diagnostic Procedure .....	232
<b>16.2</b>	<b>Communication .....</b>	<b>228</b>	16.3.4	Station 4: Communication of Results and Concluding Consultation .....	235
16.2.1	General Principles of Communication .....	229	<b>16.4</b>	<b>Summary .....</b>	<b>235</b>
16.2.2	Communication: Dealing with the Patient .....	229		<b>Bibliography .....</b>	<b>235</b>
16.2.3	Communicating Results to the Patient .....	230			
<b>16.3</b>	<b>The Patient's Flow through the Department .....</b>	<b>230</b>			
<b>Index</b>	.....				<b>237</b>

# Preface

Carcinoma in the female breast is a frequent finding in routine patient care, as it is the most common form of cancer in women. Breast cancer is a complex illness. Physicians of various specialties (e.g., radiology, gynecology, surgery, oncology) are involved with its many different aspects and our knowledge of the disease is presently growing at an incredible rate.

Advances made in recent years in the diagnosis and therapy of breast cancer pertain in large part to the study of etiological factors that increase the likelihood of developing the disease. Most of what we know about inherited breast cancer risk, for example, is based on research done in the past 10 to 15 years. There is no end in sight to the knowledge that can be gained concerning the genetic predisposition to diseases. Revolutionary progress has also been made recently in the field of diagnostic imaging. Digital mammography and modified mammographic techniques, improvements and innovations in ultrasound diagnostics, and, in particular, developments in breast MRI enabling the acquisition of high-resolution images have broadened the spectrum of available imaging procedures and dramatically improved the accuracy of breast cancer diagnosis. In addition to individualized and risk-adapted early diagnosis concepts, nationwide, population-based early diagnosis programs have been introduced. Moreover, there are now image-guided techniques available for all imaging modalities that enable the performance of reliable, low-risk, outpatient biopsies. This has sharply reduced the rate of unnecessary operations undertaken for diagnostic excision. In the field of surgery, too, there have been numerous changes and improvements. One of the greatest new advances in recent years has been the introduction of the sentinel lymph node biopsy technique, which spares many patients the burden of an unnecessary extensive lymphadenectomy, with its potential for complications. In addition, an increased range of breast-conserving operations and improved plastic-reconstructive surgical techniques are available to today's patients.

As might be expected, the approaches used in adjuvant medication and radiation therapy for treatment of breast cancer have changed and developed as well. The continual integration of new research and study results effects a constant modification and optimization of the relevant treatment concepts. Consequently, it becomes more difficult all the time for practitioners who are not directly involved in the diagnostics or treatment of breast diseases to keep up with the latest information on the topic of breast cancer.

Our aim in publishing this book is to create a reference work for physicians who are not directly involved with breast health, as well as for interested specialists and students. It gives a comprehensive overview of the most important aspects of breast cancer diagnosis and therapy, so that any unfamiliar aspects or

terms can be looked up easily and understood rapidly. The emphasis here is on a succinct presentation of the facts, guidelines, and recommendations as we know them today.

Because guidelines and recommendations vary between different countries and continents, the authors have agreed in this book to present European—i.e., German—recommendations as appropriate. In general, we have deliberately chosen not to provide lengthy explications of background information.

In preparing the chapters on diagnostics and therapy of breast cancer, we were particularly pleased to have the privilege of working with Professor Clemens F. Hess, radiotherapist and radiation oncologist; Professor Guenther Emons and his leading senior physician, Dr. Martin Hellriegel, gynecologist and gynecological oncologist; Dr. K. P. Hermann, physicist specializing in mammography; and all of the participating staff at the Women's Health Care Center in Göttingen, to create what is in essence a "Göttingen Breast Book." This is significant because Göttingen's own university medical center has for decades now made the diagnosis and treatment of breast cancer a high priority in both research and patient care.

Our particular thanks also go out to the "external" colleagues who worked with professionalism and passionate commitment to help make this book a success. First of all there is Dr. Heike Lorch, who, together with Ms. Jutta Rueschof and Ms. Anke Kuechemann, did such excellent work in preparing the chapter on counseling techniques and psychosocial guidance for women with breast cancer. Their wealth of experience and empathy shine through unmistakably. Furthermore, we extend our heartfelt thanks to Professor Thorsten Kuehn, who unfortunately no longer works in the vicinity of Göttingen. His extensive experience and pragmatic approach to breast surgery have given this book—like our previous book on breast intervention—a special additional value. We also wish to thank Professor Josef Rueschof most heartily for bringing structure and a clear overview, in his inimitable style, to the histopathological intricacies and details of breast pathology. His manner of combining text and images makes it possible for the reader to quickly grasp the morphological aspects of breast disease. In conclusion, a word to our own department: We have thoroughly enjoyed writing another book with you, Susi (a.k.a. Dr. Luftner-Nagel); discussing, critiquing, and modifying the contents, and ultimately agreeing on the final version. Thank you so much.

We hope our readers enjoy this "breast book," and wish them every success in the rapid clarification of questions on the topic of the breast.

*Prof. Uwe Fischer, MD  
Friedemann Baum, MD*

# Contributors

**Friedemann Baum, MD**

Women's Health Care Center  
Göttingen, Germany

**Guenther Emons, MD**

Professor  
Certified Breast Center of the  
University of Medicine Göttingen  
Department of Obstetrics and Gynecology  
Göttingen, Germany

**Uwe Fischer, MD**

Professor  
Women's Health Care Center  
Göttingen, Germany

**Martin Hellriegel, MD**

Certified Breast Center of the  
University of Medicine Göttingen  
Department of Obstetrics and Gynecology  
Göttingen, Germany

**Clemens-Friedrich Hess, MD, PhD**

Professor  
Certified Breast Center of the  
University of Medicine Göttingen  
Department of Radiation Therapy and Radiation Oncology  
Göttingen, Germany

**Anke Kuechemann, MA**

Women's Health Care Center  
Göttingen, Germany

**Thorsten Kuehn, MD**

Professor  
Esslingen Hospital  
Department of Obstetrics and Gynecology  
Esslingen, Germany

**Heike Lorch, MD, MA**

Associate Professor  
Aschaffenburg, Germany

**Susanne Luftner-Nagel, MD**

Women's Health Care Center  
Göttingen, Germany

**Jutta Rueschoff**

Women's Health Care Center  
Göttingen, Germany

**Josef Rueschoff, MD**

Professor  
Nordhessen Pathology  
Kassel, Germany

# Abbreviations

ABVS	automated breast volume scanner	EUSOMA	European Society of Mastology
ACR	American College of Radiology	FEA	flat epithelial atypia
ADH	atypical ductal hyperplasia	FSH	follicle-stimulating hormone
AFIP	Armed Forces Institute of Pathology	GCDFP	gross cystic disease fluid protein
AGD	average glandular dose	Gd-DTPA	gadopentetate-dimeglumine
AGO	Arbeitsgemeinschaft für gynäkologische Onkologie (Working Group for Gynecological Oncology)	GnRH	gonadotropin-releasing hormone
ALD	axillary lymph node dissection	GRE	gradient echo
AJCC	American Joint Committee on Cancer	HER	human epidermal growth factor receptor
ALH	atypical lobular hyperplasia	HPF	high power field: field of vision on enlargement
ARNO 95	Arimidex-Nolvadex 95	HRT	hormone replacement therapy
ATAC study	Anastrozole, Tamoxifen Alone or in Combination	IBCSG	International Breast Cancer Study Group
BCT	breast-conserving therapy, breast-conserving surgery	IC	intraclavicular
BIG	Breast International Group	IDC	invasive ductal carcinoma
BI-RADS	breast imaging reporting and data system	IGAP flap	inferior gluteal artery perforator flap
BRCA genes	breast cancer genes	ILC	invasive lobular carcinoma
BSA	body surface area	IPC	invasive papillary carcinoma
BW	body weight	IR	inversion recovery
BZG	Diagnostisches Brustzentrum Göttingen (Women's Health Care Center Göttingen)	ISO	International Organization for Standardization
CAD	computer-aided diagnostic system; computer-assisted detection; computer-aided diagnostics	Ki-67	proliferation index
CCC	comprehensive cancer center	LCIS	lobular carcinoma in situ
CCD detector	charge-coupled device detector	LH	luteinizing hormone
CC projection	craniocaudal projection	LIN	lobular intraepithelial neoplasia
CD	cluster of differentiation	LM projection	lateromedial projection with medially applied detector
CDMAM phantom	contrast detail mammography phantom	LVEF	left ventricular ejection fraction
CK	cytokeratin	MLO projection	mediolateral oblique projection
CLIS	carcinoma lobulare in situ (lobular carcinoma in situ)	ML projection	mediolateral projection with laterally applied detector
CT	computerized tomography, ~ tomogram	MRM	modified radical mastectomy
CTV	clinical target volume	MRM density	magnetic resonance mammographic density
DBT	breast tomosynthesis	MRI	magnetic resonance imaging
DCIS	ductal carcinoma in situ	MRS	magnetic resonance spectroscopy
DEGUM	Deutsche Gesellschaft für Ultraschall in der Medizin (German Society for Ultrasound in Medicine)	MQRA	Mammography Quality Standards Reauthorization Act
DGS	Deutsche Gesellschaft für Senologie (German Society of Senology)	mTOR kinase	Mammalian target of rapamycin kinase
DIEP flap	deep inferior epigastric perforator flap	NHSBSP	National Health Service Breast Screening Program
DIN	ductal intraepithelial neoplasia	NOS	not otherwise specified
DIN	Deutsches Institut für Normung (German Institute for Standardization)	NSABP	National Surgical Adjuvant Breast and Bowel Project
DKG	Deutsche Krebsgesellschaft (German Cancer Society)	NST	no special type
DNA	deoxyribonucleic acid	PAS	publicly available specification
EBCTCG	Early Breast Cancer Trialists' Collaborative Group	PAS stain	periodic acid-Schiff stain
eDQE	effective detective quantum efficiency	PASH	pseudoangiomatous stromal hyperplasia
EIC	extensive intraductal components	pCR	pathologically confirmed complete remission
EMA	epithelial membrane antigen	PGMI quality rating	perfect/good/moderate/inadequate (mammogram quality scoring system)
EORTC	European Organization for the Research and Treatment of Cancer	PgR	progesterone receptor
ER	estrogen receptor	PIC	predominant intraductal components
		PTV	planning target volume
		ROI	region of interest
		SC	supraclavicular


SE	spin echo
SERM	selective estrogen receptor modulator
SGAP flap	superior gluteal artery perforator flap
SIC	small intraductal components
SISH	silver in-situ hybridization
SLN	sentinel lymph node
SLNB	sentinel lymph node biopsy
SMA	smooth-muscle actin
T1W	T1-weighted
T2W	T2-weighted
TDLU	terminal duct lobular unit
TE	echo time
TGC	time gain compensation
TIC	time–signal intensity curve
TR	repetition time
TRAM flap	transverse rectus abdominis- musculocutaneus flap
TSE	turbo spin echo
UDH	usual ductal hyperplasia
UICC	Union for International Cancer Control/ Union internationale contre le cancer
VEGF	vascular endothelial growth factor
WHO	World Health Organization





## Part 1

### Anatomy, Physiology, and Pathology of the Breast



# 1 Development, Anatomy, and Physiology of the Mammary Gland

F. Baum

## 1.1 Development

Mammals (from the Latin *Mammalia*) are named for the fact that they feed their young on milk produced in the *mammary* gland. The various species of mammals have developed different numbers of mammary glands along the genetically determined milk line.

Mammalian breasts generally occur in pairs, as is the case in humans. Normally, humans have one breast on each side of the chest. At the prepubescent stage, both girls and boys have mammary buds. With the onset of puberty, the production of estrogen increases in the female body, causing changes in the mammary gland: the breast buds enlarge and the breast exhibits an increased build-up of adipose tissue. Milk is secreted in the mammary gland even when there is no pregnancy, but the volume of this basic secretion varies widely from one individual to the next, and often goes unnoticed.

## 1.2 Anatomy

The network of lactiferous ducts resembles a coral bush (► Fig. 1.1). From the point of exit at the nipple (mamilla), the milk ducts branch out within the breast, with a smaller duct diameter after each divergence. At the periphery, the smallest milk ducts originate from the lobules of the gland, where the milk is secreted. Some 30 of these milk ducts, leading from all four quadrants of the breast, open out into the mamilla and thus form the functional unit of the mammary gland.

The lobules are embedded in a network of connective tissue that permeates the breast, extending outward in an arc from

somewhere in the deep fascia. Known as Cooper's ligaments, this tissue helps to provide structural integrity, supporting both lobules and adipose tissue. The ratio of fat to glandular tissue in the human breast varies widely between individuals, from almost 100% fat to almost 100% glandular tissue. In mammography, this is referred to as a lipomatous or an extremely dense parenchymal type, respectively.

In addition to the secretory unit, made up of lobules and milk ducts, the mammary gland also contains lymph nodes that protect the body from bacterial incursion. Bacteria can enter through the milk duct openings at the nipple. The lymph nodes are commonly located in the upper outer quadrants, but have also been detected in the other three quadrants. Lymph flow is chiefly toward the underarm (axilla), first to the sentinel lymph node and from there to the other axillary lymph nodes. Only a very small portion enters the thoracic cavity via the parasternal lymph nodes. The arterial blood supply to the breast is carried mainly by the medial mammary branches of the internal thoracic artery (ca. 60%) and by the lateral mammary branches of the lateral thoracic artery (ca. 30%). Venous drainage is through the corresponding veins.


## 1.3 Physiology

The physiology of the mammary gland is controlled entirely by hormones. Metabolic activity in the mammary gland varies under the influence of estrogen. Even in childhood, hormonal fluctuations can occasionally cause swelling of the mammary bud. But this is usually a temporary phenomenon that reverts within a short time.

From the onset of menses, or menarche, many women observe changes in the mammary gland that recur every month. Following ovulation and approximately one week prior to menstruation, there is sometimes tenderness or a painful sensation of pressure in the breast, in some cases accompanied by swelling. These phenomena are triggered by the temporary gestagen production in the fallopian tubes, which usually abates when menstruation begins.

When pregnancy occurs and the fertilized egg implants in the uterine wall, the placenta begins producing chorionic gonadotropin. This stimulates the corpus luteum, which in turn triggers continuous secretion of progesterone, essential for maintaining the placenta in the uterus. The continuing production of progesterone during pregnancy also triggers further differentiation in the mammary gland and considerable growth of the milk-secreting lobules. The stimulation due to sucking, in the nursing phase, increases the secretion of the hormones prolactin and oxytocin by the pituitary gland. It is the interaction of these hormones which triggers the production of milk in the mammary gland, or lactation.

The effects of progesterone and prolactin on the mammary gland are reversible: the breast returns to its inactive state once breast feeding has ended. After weaning, the stimulation of the



**Fig. 1.1 The course of a milk duct.** A mammary duct divides numerous times from the nipple. The smallest milk ducts originate from the lobules of the gland at the periphery and the milk is conducted from many lobules to the mamilla.

mammary gland by prolactin and oxytocin is reduced, causing the gland lobules to become smaller and fewer. The changes in the breast that occurred with lactation are thus completely undone.

In menopause, the hormonal stimulation of the glandular tissue decreases considerably. Normally, there is also a reduction of glandular tissue in this phase, which increases the transparency of the mammary gland in mammography.

## Bibliography

- [1] Kaufmann M, Costa SD, Scharl A. Die Gynäkologie. 3. Aufl. Berlin: Springer; 2012
- [2] Keidel WD. Kurzgefasstes Lehrbuch der Physiologie. 2. Aufl. Stuttgart: Thieme; 1970
- [3] Netter FH. Atlas der Anatomie des Menschen. 3. Aufl. Stuttgart: Thieme; 2003

## 2 Tumor Formation

F. Baum

2

### 2.1 Mutation, Carcinogenesis, and Angiogenesis

Life on earth is based on genes that are passed on from one generation to the next. Genetic material is transmitted in the form of nucleic acids (DNA) contained within the chromosome, which is in the nucleus of the cell. Each time a cell divides, it creates a complete copy of itself. Any errors that occur while the genetic information is being replicated are termed mutations. Considering the extensive amount of data contained within DNA, such errors are unavoidable. For the most part, these small mutations have no physiologically significant effect, but in some cases the resulting change is incompatible with the cell's life processes. In very rare cases, the mutation actually increases the new cell's chances of survival over those of the original cell. Throughout many millions of years and countless generations, this process has cumulatively led to a huge diversity of species.

Seen over the course of generations, mutation is what drives evolution—but in an individual it can endanger health and even life. A genetic mutation that changes the physiological properties of an organism may have any of a number of effects. If the modified cell continues to “play by the rules” of the organism then the mutation generally presents no danger.

If a cell loses its characteristic property of living within a community of cells, however, then it has become what we call a cancer cell. Generally, a series of six to eight mutations is required before this point is reached. Specifically, cancer cells lack the property of “contact inhibition,” the trait that inhibits cell migration into other cells and organs (► Fig. 2.1). In a manner of speaking, contact inhibition is what regulates the different “territories” in multicellular organisms. It prevents cells from spreading into organs in which they do not belong.


The loss of contact inhibition makes it possible for a cancer cell to infiltrate foreign tissue. This process is aided by certain enzymes that dissolve connective tissue and other structures. Furthermore, cancer cells can leave their point of origin and move via lymph vessels and blood vessels. These processes are termed lymphatic spread and hematogenous spread, respectively, and can lead to the formation of metastases.

Cancer cells are characterized by an accelerated metabolism and an exceedingly rapid cell cycle. They thus have particularly high nutritional requirements. To meet their extensive needs, these cells secrete enzymes that stimulate the surrounding tissue to rapidly form a system of capillaries, a process termed angiogenesis or tumor angiogenesis. These new capillaries are morphologically simple endothelial tubes that lack the complex structure of normal blood vessels but suffice to enable the development of carcinoma cells and to supply them. This capillary network drains energy and nutrients from the surrounding organs, and consequently from the overall organism. Sometimes, however, cancer cells grow so rapidly that even the dedicated blood supply cannot feed all parts of the tumor, and cancer cells begin to die, usually in the center of the tumor.

### 2.2 Risk Factors

The probability that a woman will develop breast cancer at some point in her life depends on a number of different factors (► Table 2.1, ► Table 2.2). Oncogenes and tumor suppressor genes play an important role in the regulation of healthy cell growth and tumor development. Oncogenes accelerate cell growth, while tumor suppressor genes slow it down.

On average, a woman in Europe has an 11% chance of developing breast cancer. In industrialized countries, the incidence



**Fig. 2.1 Tumor development.** (a) A mutated cell clone (gray) has evolved within a milk duct from the epithelium (white). (b) Over time, a second (green) and a third (orange) mutation occur. (c) Further mutations in the course of time; e.g., up to a sixth mutation (red). (d) This cell clone has lost its contact inhibition and thus supplants the surrounding cells. (e) With further time, the cell clone has penetrated the boundaries of anatomical structures: it has become an invasive tumor.

**Table 2.1** Absolute breast cancer risk by age (from Royal New Zealand College of General Practitioners [RNZCGP]. Early detection of breast cancer 1999. Wellington, New Zealand: RNZCGP;1999:1–61)

Risk of disease	Age group (years)			
	25–44	45–54	55–79	> 80
Absolute 5-year risk (%)	< 0.5	0.5–1	1–1.5	1.5–2
Per 1,000 women	< 5	5–10	10–15	15–20

**Table 2.2** Relevant risk factors for developing breast cancer, in descending order of significance (from Deutsche Gesellschaft für Senologie e.V., Deutsche Krebshilfe e.V. S3-Leitlinie “Brustkrebs-Früherkennung in Deutschland”. 1. Aktualisierung. München: W. Zuckschwerdt; 2008)

Risk factors	Relative risk
Cancer in childhood	20
Radiotherapy (age 9–15 years)	10
Mantle-field radiotherapy	10
High-risk	4.0–10
Type ACR IV tissue density	3.8–5.2
Status post surgery for contralateral carcinoma:	
• Age <45 years	5.0–9.0
• Age 45–59 years	3.7–4.1
• Age ≥60 years	1.8–3.0
Status post surgery for DCIS (premenopause)	5
Status post surgery for ADH	2.0–4.0
Menarche at age <11 years	3
Menopause at age >54 years	2
Abbreviations: ACR, American College of Radiology; ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ.	

of breast cancer is rising and the average age of initial illness is dropping. In Asia and Africa, this risk is significantly lower, which suggests that certain lifestyle factors may play a significant role. In those parts of China, for example, where Western standards of living have been introduced, the incidence of breast cancer is increasing accordingly. One possible explanation for this is the decreased bodily production of melatonin as a result of the use of artificial light, which shortens the night phase. This results in an increased risk of breast cancer. A lower risk of breast cancer is seen among women who have late menarche or early menopause, and among those who bear and breast-feed children. The risk is increased, on the other hand, by such factors as obesity, alcohol consumption, and lack of physical exercise. Female hormone replacement therapy—in particular if hormones are taken for long periods—increases the risk of breast cancer 1.5- to 3-fold.

### Take Home Points

- **Age and breast cancer risk:** The most important population-based risk factor for breast cancer is increasing age.
- **Mammographic density and breast cancer risk:** A high mammographic density (ACR III or IV) is one of the greatest individual risk factors.

## 2.3 Genetic Risk Factors

In addition to lifestyle-related factors, genetic factors can also affect a woman's risk of breast cancer. In families with a high

**Table 2.3** High-risk genes with known germline mutations and associated lifetime risk of breast or ovarian carcinoma

Gene	Percent lifetime risk of	
	Breast carcinoma	Ovarian carcinoma
BRCA1 (detectable)	80	45
BRCA2 (detectable)	80	20
BRCA3 (detectable)	?	?
BRCA4	?	?

incidence of breast cancer, an individual's lifetime risk of developing breast cancer can be as high as 80%. In these families there is also an increased incidence of ovarian carcinoma.

The high incidence of these cancers in high-risk families is due to defects in repair enzymes, which play an important role in cell division in both organs. These enzymes are proteins that check and correct the double-stranded DNA during the cell division process, normally reducing the number of mutations. If the genes coding for these repair enzymes are altered, then these enzymes can lose either the ability to detect replication errors or the ability to correct detected replication errors. These defective enzyme genes are called breast cancer (or *BRCA*) genes (► Table 2.3). Other genes associated with breast/ovarian cancer are *RAD51C* and *RAD51D*. It has also long been known that persons who have ataxia telangiectasia or Li-Fraumeni syndrome have a higher risk of breast cancer.

*BRCA* mutations are inherited in an autosomal dominant inheritance pattern: they can be inherited from father or mother. If one parent carries this mutated gene, each child has a 50% chance of inheriting it.

### Note

It can be assumed that some 5 to 10% of all women who have breast carcinoma have an autosomal dominant genetic predisposition.

The presence of an autosomal dominant inheritable germline mutation with a probability of more than 10% may be assumed if one of the following constellations exists within the family:

- At least three women with breast cancer, regardless of age.
- At least two women with breast cancer, one of them before age 50 years.
- At least two women with ovarian cancer.
- At least one woman with breast cancer and one woman with ovarian cancer.
- At least one woman with both breast cancer and ovarian cancer.
- At least one woman with breast cancer diagnosed before age 36 years.
- At least one woman with bilateral breast cancer diagnosed before age 51 years.
- At least one man with breast cancer and one woman with breast or ovarian cancer.

Some cancer societies see a high-risk constellation in families in which women develop breast or ovarian cancer at an early age:

- Two women with breast and/or ovarian cancer diagnosed before age 50 years.

- One woman with unilateral breast cancer diagnosed before age 30 years.
- One woman with bilateral breast cancer diagnosed before age 40 years.
- One woman with ovarian cancer diagnosed before age 40 years.

Consultation at a specialized and interdisciplinary facility is recommended for individuals from families with a potentially high-risk constellation. These facilities provide counseling and can check whether the inclusion criteria indicate that genetic testing is advisable.

## 2.4 Prevention

### 2.4.1 Primary Prevention

Primary prevention refers to the prevention of the development of disease in the first place. The removal of benign polyps during a colonoscopy can, for example, prevent the development of malignant colorectal tumors. In the case of breast cancer, primary prevention consists in removing both breasts (bilateral mastectomy).

### 2.4.2 Secondary Prevention

The aim of secondary prevention is to detect the disease in the earliest possible stage. The three imaging modalities most commonly used for the detection of breast cancer are mammography, ultrasound, and magnetic resonance imaging (MRI). The aim of using these procedures is to detect changes in the breast that are characteristic of carcinomas. Each method has its own particular strengths and the detectability of alteration in tissues depends on factors such as the size of a tumor and, in particular, the ability to distinguish tissue with breast cancer changes from the surrounding normal structures.

The standard method used in early detection of breast cancer is X-ray mammography: the *breast radiograph*. The sensitivity of mammography is approximately 70%, with a specificity (i.e., accuracy) of about 90%. The same figures are obtained with breast ultrasonography for the early detection of breast carcinomas. However, both methods show considerably lower values for both sensitivity and specificity in detecting tumors of 5 to 10 mm diameter. The most reliable technique for the early detection of

breast carcinoma is MRI of the breast. Available study data indicate that both the sensitivity and the specificity of this examination are greater than 90%. This also applies for tumors between 5 and 10 mm in size, but only when stringent quality control standards are applied.

Early-detection diagnostics are not the same as a diagnostic work-up. The latter is applied when symptoms such as pain, palpable lumps, retractions, discoloration, or bleeding are reported.

#### Note

The objective of early-detection diagnostics is to detect tumors before clinical changes have occurred.

### 2.4.3 Tertiary Prevention

Tertiary prevention consists in minimizing complications and recurrences once cancer has developed.

## 2.5 Epidemiology, Incidence, and Mortality

Breast carcinoma is the most common cancer in women in Western societies. Approximately one woman in nine will have breast cancer at some point in her life. This ratio includes a large number of women with a normal lifetime risk (6–8%) and a somewhat lower number of women who have an individual high-risk profile (lifetime risk ca. 80%).

Some 72,000 new cases of breast carcinoma are diagnosed each year in Germany. In many other regions around the world, the risk is much lower. The incidence of a disease is defined as the number of new cases diagnosed per 100,000 women per year. In Germany, breast carcinoma incidence is about 120 per 100,000 women per year.

Breast cancer also has the highest mortality rate for women, accounting for some 17.3% of cancer deaths among women. The mortality rate is defined as the number of deaths caused per 100,000 women per year. In Germany, the mortality rate for breast cancer is about 40 per 100,000 per year. Some 17,000 patients per year die in Germany as a result of breast cancer (► Fig. 2.2, ► Fig. 2.3).






Fig. 2.2 Relative percentages of the most common tumor locations among all new cancer cases in men and women in the USA in 2015 (from American Cancer Society <https://www.cancer.org/search.html?q=Cancer%20Fact%20and%20Statistics%202011>).




Fig. 2.3 Relative percentages of the most common tumor locations among all cancer deaths in men and women in the USA in 2015 (American Cancer Society <https://www.cancer.org/search.html?q=Cancer%20Fact%20and%20Statistics%202011>).

## Bibliography

- [1] Adami HO, Bergström R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. *Cancer*. 1985; 55(3):643–647
- [2] Aranda FI, Laforga JB. Microvessel quantitation in breast ductal invasive carcinoma. Correlation with proliferative activity, hormonal receptors and lymph node metastases. *Pathol Res Pract*. 1996; 192(2):124–129
- [3] Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. *N Engl J Med*. 1996; 334(12):745–751
- [4] Bicknell R, Harris AL. Mechanisms and therapeutic implications of angiogenesis. *Curr Opin Oncol*. 1996; 8(1):60–65
- [5] Brinck U, Fischer U, Korabiowska M, Jutrowski M, Schauer A, Grabbe E. The variability of fibroadenoma in contrast-enhanced dynamic MR mammography. *AJR Am J Roentgenol*. 1997; 168(5):1331–1334
- [6] Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. *Radiology*. 1996; 200(3):639–649
- [7] Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. *J Magn Reson Imaging*. 1997; 7(3):461–464
- [8] Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. *J Natl Cancer Inst*. 1995; 87(21):1622–1629
- [9] Eckart WU. 100 Jahre organisierte Krebsforschung; Thieme, Stuttgart; 2000

- [10] Folkman J, Klagsbrun M. Angiogenic factors. *Science*. 1987; 235 (4787):442–447
- [11] Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. *N Engl J Med*. 1995; 333 (26):1757–1763
- [12] Frouge C, Guinebretière JM, Contesso G, Di Paola R, Bléry M. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. *Invest Radiol*. 1994; 29(12):1043–1049
- [13] Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. *J Natl Cancer Inst*. 1993; 85(1):25–31
- [14] Hulka CA, Edmister WB, Smith BL, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. *Radiology*. 1997; 205(3):837–842
- [15] Kaste SC, Hudson MM, Jones DJ, et al. Breast masses in women treated for childhood cancer: incidence and screening guidelines. *Cancer*. 1998; 82 (4):784–792
- [16] Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft eV und Deutschen Krebshilfe eV. Leitlinienreport der S 3 Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. AWMF Register-Nr. 032–045OL. München: W. Zuckschwerdt Verlag GmbH 2012
- [17] London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. *JAMA*. 1992; 267(7):941–944
- [18] Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet*. 2001; 358(9291):1389–1399
- [19] Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. *Cancer*. 1993; 71(11):3547–3551
- [20] Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. *Semin Oncol*. 1997; 24(2):203–218
- [21] Robert K-I. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Krebs in Deutschland 2007/2008. 8. Ausgabe. Berlin: Robert Koch-Institut; 2012
- [22] Royal New Zealand College of General Practitioners (RNZCGP). Early Detection of Breast Cancer 1999. Wellington, New Zealand: RNZCGP; 1999: 1–61
- [23] Schmoll HJ, Höffken K, Possinger K. Kompendium Internistische Onkologie. 4. Aufl. Berlin: Springer; 2005
- [24] Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. *Maturitas*. 2002; 41(3):171–175
- [25] Stomper PC, Herman S, Klippenstein DL, Winston JS, Budnick RM, Stewart CC. Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage. *Cancer*. 1996; 77(9):1844–1849
- [26] Szabó BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Boné B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. *Eur Radiol*. 2003; 13(11):2425–2435
- [27] Talamini R, Franceschi S, La Vecchia C, et al. The role of reproductive and menstrual factors in cancer of the breast before and after menopause. *Eur J Cancer*. 1996; 32A(2):303–310
- [28] Teifke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. *Radiology*. 2006; 239(2):351–360
- [29] Tuncbilek N, Unlu E, Karakas HM, Cakir B, Ozyilmaz F. Evaluation of tumor angiogenesis with contrast-enhanced dynamic magnetic resonance mammography. *Breast J*. 2003; 9(5):403–408
- [30] Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. *N Engl J Med*. 1991; 324(1):1–8
- [31] Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. *J Natl Cancer Inst*. 1992; 84(24):1875–1887
- [32] Yarbrow JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on Cancer prognostic factors consensus conference. *Cancer*. 1999; 86(11):2436–2446



## 3 Pathology of Benign and Malignant Changes in the Breast

J. Rueschoff

### 3.1 Benign Changes

#### 3.1.1 Histological Principles

The breast is made up of 15 to 25 glands (lobules or segments) (► Fig. 3.1a). These glands comprise a dense system of bifurcating ducts and ductules ending in the milk-secreting lobules (acini; ► Fig. 3.1b). The large majority of breast diseases originate in the epithelial cells that line the ducts and lobules. The most frequent point of origin is at the ends of the glandular “tree,” the terminal duct lobular unit (TDLU) (► Fig. 3.1c, d).

Immunohistochemically, the luminal cell layer (both glandular and ductal) and the basal myoepithelial cell layer develop from a progenitor cell expressing basal (high molecular weight) cytokeratins (CK5/6 or CK5/14). The mature myoepithelial cell may revert to being CK5/6 negative, though myofilaments with antibodies for smooth muscle actin (SMA) and CD10<sup>32</sup> can be detected. Mature luminal duct and gland cells are positive for the low molecular weight cytokeratin CK8/18, but negative for CK5/6 (progenitor cell model<sup>1,7</sup>).

#### 3.1.2 Nonneoplastic, Nonproliferative Diseases of the Breast


Diseases of the breast are among the most common disorders of organs in women and are often associated with the formation of

a palpable lump. In principle breast diseases can also develop in men. It is important to distinguish between palpable lumps caused by true new tissue growth (tumor or neoplasia) and those that do not exhibit uncontrolled, progressive growth (nonneoplastic, pseudotumorous). Because breast tissue is hormone-responsive, changes occur particularly during the menstrual cycle but also during pregnancy and lactation, which can sometimes promote changes such as the formation of cysts (mastopathy), or inflammatory processes (mastitis). In individual cases it can be difficult, not only clinically and in breast imaging, but also pathologically, to distinguish nonneoplastic benign changes from neoplastic malignant lesions. Indeed, a reliable evaluation of pathological findings in the breast can be a challenge even for pathologists. In the following subsections, the typically diffuse changes in breast tissue are described and distinguished from those lesions that typically lead to tumor formation.

#### Defects and Supernumerary Structures

Congenital abnormalities of the breast are relatively rare and are divided into defects and supernumerary structures:

- Defects: These range from the complete absence of breast tissue and nipple (amastia) to isolated abnormalities of the nipple (athelia, microthelia) or the breast (amastia, aplasia) and to bilateral or unilateral underdevelopment of the breast (micromastia, anisomastia).



**Fig. 3.1 Anatomy of the breast.** (a, b) Schematic diagrams. (c, d) histology and immunohistochemistry. (a) Mammary gland with ca. 15 to 25 individual lobes, each ending at the nipple orifice. (b) Detail from (a): The branching ducts lead into terminal ducts (ductules) and end in the secretory lobes (acini). (c) Terminal duct lobular unit (TDLU). (d) TDLU with a luminal (blue nuclei) and a basal myoepithelial cell layer (brown represents CD10).

- **Supernumerary structures:** Supernumerary nipples (polythelia) and/or breasts (polymastia) develop in the milk line and are found in approximately 3% of the population, with no gender preference. The most common localizations of such formations are in the axilla (45% of cases), near the breast (25%), and in the medioclavicular line of the chest wall (12%). Carcinomas in a mamma aberrata (dystopic carcinomas) are rare and are prognostically unfavorable.<sup>40</sup>

## Macromastia

The term “macromastia” (diffuse hypertrophy of the breast) refers both to premature (infantile) breast development and to excessive growth of the breast beyond what is age-appropriate. Macromastia occurs most frequently in adolescence, with proliferation of ductal epithelia and fibrosis of breast tissue being the most prominent histological features. Most commonly there is an increase in fatty tissue (lipomatous macromastia). In the differential diagnosis, the following secondary forms must be distinguished from primary macromastia:

- **Paraneoplastic:** in the case of endocrine-active tumors (hypophyseal adenoma, small-cell bronchial carcinoma, Cushing's disease, acromegaly, dysgerminoma).
- **Drug related** (digitalis).
- **Tumor-related:** by infiltration of the breast tissue (malignant lymphomas).

## Fibrocystic Mastopathy

Characteristic features of a simple fibrocystic breast condition are morphological changes in which fibrosis of the mammary tissue with duct ectasia is predominant but not epithelial proliferation. Such changes can be detected in ca. 50% of women age 30 years and over and are considered by some authors to be a variant of the norm with no pathological significance. There is no associated increased risk of breast cancer.<sup>1</sup>

Typical histological findings include the following changes:

- **Cysts and duct ectasia:** The lactiferous ducts are noticeably enlarged but generally show an intact epithelial lining (► Fig. 3.2), although solitary cysts (larger than 1 cm) may form.
- **Fibrosis:** This is an intralobular or perilobular collagen fiber proliferation in the breast stroma.
- **Metaplasia:** This is usually an apocrine metaplasia with cylindrical, red eosin-stained epithelia (similar to sweat glands).

## Mastitis


Inflammations of the breast are either acute (usually bacterial infection) or mainly chronic (usually resulting from retention of secretion). Reactive specific and granulomatous inflammatory changes are rare.<sup>2</sup>

### Acute Mastitis

Acute inflammations (thelitis, areolitis) are usually caused by contact infection during breastfeeding and can lead to a canalicular transmission of the inflammation to the glandular tissue (puerperal mastitis). The most frequent pathogen (95% of cases) is *Staphylococcus aureus* from the nasopharyngeal cavity of the child, the mother, or the nursing staff. Purulent inflammations of the mammary gland (nonpuerperal mastitis) are rare after the postnatal period. These develop due to displacement of the lactiferous duct by nipple calluses, scars, or tumors with subsequent retention of secretions. Secondary colonization can then lead to formation of a suppurating abscess. Histologically, there is a leukocytic infiltration of the milk ducts and lobules with invasion of the mantle and supporting tissue. Healing of abscesses and fistulas can leave scarring and deformation of the breast.

### Chronic Periductal Mastitis (Retention Syndrome)

About one-third of nonpuerperal mastitis cases are nonbacterial, chemically induced inflammations caused by intraductal secretion retention (► Fig. 3.3a). Histological features include ectatic



**Fig. 3.2 Fibrocystic mastopathy.** (a) Cystic duct ectasia. (b) Fibrocystic tissue transformation with ectatic ductules, partly lined by (reddish) apocrine metaplastic epithelium (A), and incipient focal lobule sclerosis (S). (From Bock K, Ramaswamy A, Köhler H. Fortbildungskurs zur Aufrechterhaltung und Weiterentwicklung der fachlichen Befähigung für Pathologen [6.10.2012]—Referenzzentrum Mammographie Südwest am Universitätsklinikum Gießen-Marburg am Standort Marburg [Course text].)